Glioblastoma Multiforme Brain Tumor
Links shared publicly online about this topic
NovoTTF-100A System Approved for Recurrent Glioblastoma Multiforme Brain Tumors - ONA
oncologynurseadvisor.com — “Novocure announced that the NovoTTF-100A System has been approved by the FDA for the treatment of adult patients with glioblastoma multiforme brain tumors, following tumor recurrence after receiving chemotherapy.” View full resource at oncologynurseadvisor.com
Most Recently Shared on April 18, 2011 at 4:12 pm By:
OncologyNurseAdvisor Oncology, Nursing, Medical Education, and Medical Publisher
NovoTTF-100A System Approved for Recurrent Glioblastoma Multiforme Brain Tumors http://goo.gl/fb/HkkHC
Glioblastoma Multiforme: eMedicine Neurology
emedicine.medscape.com — “Overview: Glioblastoma multiforme (GBM) is the most common and most aggressive of the primary brain tumors. The current World Health Organization (WHO) classification of primary brain tumors lists GBM as a grade IV astrocytoma. Astrocytoma is one ...” View full resource at emedicine.medscape.com
Most Recently Shared on April 29, 2010 at 8:56 pm By:
Medscape Neurology Neurology and Health Site
Glioblastoma Multiforme: http://bit.ly/doGALc
Glioblastoma Multiforme: eMedicine Neurology
emedicine.medscape.com — “Overview: Glioblastoma multiforme (GBM) is the most common and most aggressive of the primary brain tumors. The current World Health Organization (WHO) classification of primary brain tumors lists GBM as a grade IV astrocytoma. Astrocytoma is one ...” View full resource at emedicine.medscape.com
Most Recently Shared on September 9, 2009 at 4:29 pm By:
Medscape Neurology Neurology and Health Site
eMedicine article Glioblastoma Multiforme updated for 2009. #health #medicine #neurology #brain tumor http://bit.ly/eZF6h
Glioblastoma multiforme in the Dock
eurekalert.org — “Glioblastoma multiforme is the most common malignant brain cancer in humans. Patients with this highly aggressive form of cancer have a poor prognosis because it is commonly resistant to current therapies. Researchers have now identified a molecular pathway that drives the aggressive cancerous nature of a many glioblastomas; specifically, those that overexpress the protein PDGFR-alpha. This pathway could represent a novel and attractive therapeutic target for treating individuals with glioblasto” View full resource at eurekalert.org
Most Recently Shared on November 14, 2011 at 7:41 pm By:
Glioblastoma multiforme in the Dock: ( Journal of Clinical Investigation ) Glioblastoma multiforme is the most c... http://t.co/dZA2WIz2
The JFK New Jersey Neuroscience Institute in Edison to Offer New Treatment for Recurrent Glioblastoma Multiforme, a Deadly Brain Tumor
jfkmc.org — “The JFK New Jersey Neuroscience Institute in Edison to Offer New Treatment for Recurrent Glioblastoma Multiforme, a Deadly Brain Tumor” View full resource at jfkmc.org
Most Recently Shared on December 6, 2011 at 9:38 pm By:
The JFK New Jersey Neuroscience Institute has announced that it is one of four cancer centers in the U.S. to... http://t.co/lXImpeeT
Scientists discover new signaling pathway to reduce tumour growth in glioblastoma multiforme
news-medical.net — “Malignant gliomas are the most common subtype of primary brain tumor - and one of the deadliest. Even as doctors make steady progress treating other types of solid tumor cancers, from breast to prostate, the most aggressive form of malignant glioma, called a glioblastoma multiforme or GBM, has steadfastly defied advances in neurosurgery, radiation therapy and various conventional or novel drugs. But an international team of scientists, headed by researchers at the Ludwig Institute for Cancer Res” View full resource at news-medical.net
Most Recently Shared on August 16, 2010 at 5:58 am By:
Scientists discover new signaling pathway to reduce tumour growth in glioblastoma multiforme: Malignant gliomas ar... http://bit.ly/bB9Zy0
ImmunoCellular provides update on ICT-107 Phase II trial for glioblastoma multiforme
news-medical.net — “ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, provided an update today on clinical trial site activity and patient enrollment for its Phase II clinical trial of ICT-107, the Company's dendritic cell based cancer vaccine candidate targeting multiple tumor antigens for the treatment of glioblastoma multiforme.” View full resource at news-medical.net
Most Recently Shared on September 7, 2011 at 2:05 pm By:
News-Medical.Net Health News and Oncology
Oncology News: ImmunoCellular provides update on ICT-107 Phase II trial for glioblastoma multiforme: ImmunoCellu... http://t.co/eFnQJgp
Clinical Trials for Brain Tumors in Tennessee
methodisthealth.or-live.com — “The Methodist Brain & Spine Institute in Tennessee conducts clinical trials designed to determine the safety and effectiveness of new brain tumor treatments.” View full resource at methodisthealth.or-live.com
Most Recently Shared on April 28, 2010 at 5:42 pm By:
Methodist Healthcare Healthcare System
The Memphis Regional Brain Tumor Center is currently conducting 2 clinical trials on Glioblastoma Multiforme: http://bit.ly/a45axi
Brain Tumor Chemotherapy Resistance Prediction
medicalnewstoday.com — “Glioblastoma multiforme (GBM) is the most common and lethal of all human brain tumors that originate in the brain. For most patients, treatment involves surgery followed by both radiatio” View full resource at medicalnewstoday.com
Most Recently Shared on December 13, 2011 at 10:05 am By:
Matti Waananen, MD Surgeon, Neurosurgeon, Physician, and Doctor
Brain Tumor Chemotherapy Resistance Prediction http://t.co/rm5LCttz via @mnt_cancer
University Of Basque Country Thesis Shows That Multidisciplinary Treatment Of Glioblastoma Multiforme Can Extend Patient's Life
medicalnewstoday.com — “Glioblastoma multiforme is the most common form of brain cancer; being an extremely serious type of the disease as currently, on diagnosis, the chances of survival of the patient is less than a ye” View full resource at medicalnewstoday.com
Most Recently Shared on August 13, 2010 at 3:00 pm By:
MNT Neurology News Neurology and Health News
University Of Basque Country Thesis Shows That Multidisciplinary Treatment Of Glioblastoma Multiforme Can Extend Patie... http://mnt.to/3Hkk
BMC Cancer | Abstract | Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol
biomedcentral.com — “The treatment of patients with malignant brain tumors remains a major oncological problem. The median survival of patients with glioblastoma multiforme (GBM), the most malignant type, is only 15 months after initial diagnosis and even less after tumor recurrence. Improvements of standard treatment including surgery and radio-chemotherapy have not lead to major improvements. Therefore, alternative therapeutics such as oncolytic viruses that specifically target and destroy cancer cells are under i” View full resource at biomedcentral.com
Most Recently Shared on March 22, 2012 at 4:39 pm By:
Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (... http://t.co/kOwrrDFN
FDA advisory panel votes in favor of NovoTTF-100A System for supra-tentorial glioblastoma multiforme tumors
news-medical.net — “Novocure announced today that the U.S. Food and Drug Administration (FDA) Neurological Devices Advisory Panel of the Medical Devices Advisory Committee voted (7 yes; 3 no; 2 abstain) that for patients with supra-tentorial glioblastoma multiforme (GBM) tumors that recur after maximal surgical and radiation treatments, there is reasonable assurance that the benefits of the NovoTTF-100A System (NovoTTF) outweigh its risks when administered as a monotherapy in place of standard medical therapy.” View full resource at news-medical.net
Most Recently Shared on March 18, 2011 at 12:57 pm By:
News-Medical.Net Health News and Oncology
Oncology News: FDA advisory panel votes in favor of NovoTTF-100A System for supra-tentorial glioblastoma multifo... http://bit.ly/hcTqZC
Oncology Article | Glioblastoma
mdlinx.com — “Sagopilone (ZK-EPO, ZK 219477) for recurrent glioblastoma. A phase II multicenter trial by the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group” View full resource at mdlinx.com
Most Recently Shared on March 4, 2011 at 12:15 pm By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Sagopilone (ZK-EPO, ZK 219477) for recurrent glioblastoma. A phase II multicenter trial by the Europea... http://bit.ly/dFJtv9 #oncology
A Rare Happy Outcome For Glioblastoma Diagnosis
medicalnewstoday.com — “John Moran was 27 years old when he underwent a longshot brain surgery for what appeared to be malignant tumor that would almost certainly be fatal.But Loyola University Medical Center ne” View full resource at medicalnewstoday.com
Most Recently Shared on March 24, 2011 at 7:05 pm By:
MNT Neurology News Neurology and Health News
A Rare Happy Outcome For Glioblastoma Diagnosis http://mnt.to/3SHY #neurology
Study: Gamma secretase and temozolomide drug combination improved survival in mice with glioblastoma multiforme http://bit.ly/dzlQjh #health
reuters.com — “Study: Gamma secretase and temozolomide drug combination improved survival in mice with glioblastoma multiforme http://bit.ly/dzlQjh #health” View full resource at reuters.com
Most Recently Shared on August 24, 2010 at 9:15 pm By:
Hisham Rana, MD Doctor and Physician
Study: Gamma secretase and temozolomide drug combination improved survival in mice with glioblastoma multiforme http://bit.ly/dzlQjh #health
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Related WisdomCards
Related Health Centers
Featuring the top 3 experts for this topic
-
OncologyNurseAdvisor
Oncology Nurse Advisor offers clinical updates and evidence-based guidance to the oncology nurse community and includes regular coverage of a variety of topics.
-
Medscape Neurology
News, full text journal articles, clinical reference, expert commentary & community features vital for todays neurology
-
Medscape Neurology
News, full text journal articles, clinical reference, expert commentary & community features vital for todays neurology
Advertisement
